Orchard Therapeutics Current Ratio 2017-2021 | ORTX

Orchard Therapeutics current ratio from 2017 to 2021. Current ratio can be defined as a liquidity ratio that measures a company's ability to pay short-term obligations.
Orchard Therapeutics Current Ratio Historical Data
Date Current Assets Current Liabilities Current Ratio
2021-06-30 $0.30B $0.04B 7.43
2021-03-31 $0.33B $0.05B 6.77
2020-12-31 $0.22B $0.05B 4.34
2020-09-30 $0.23B $0.04B 5.74
2020-06-30 $0.26B $0.04B 6.07
2020-03-31 $0.30B $0.05B 6.66
2019-12-31 $0.35B $0.06B 6.26
2019-09-30 $0.39B $0.04B 8.88
2019-06-30 $0.44B $0.06B 7.89
2019-03-31 $0.32B $0.04B 9.18
2018-12-31 $0.36B $0.05B 7.42
2018-09-30 $0.00B 0.00
2018-06-30 $0.06B $0.04B 1.37
2018-03-31 $0.00B 0.00
2017-12-31 $0.09B $0.01B 8.76
2016-12-31 $0.00B $0.00B 1.04
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $0.237B $0.003B
Orchard Therapeutics plc is a biopharmaceutical company. It offers medical research, gene therapy and inherited disorder treatment services which transforms the lives of patients with serious and life-threatening rare diseases through autologous ex vivo gene therapies. Orchard Therapeutics plc is based in London, United Kingdom.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $127.994B 8.52
Bio-Rad Laboratories (BIO.B) United States $21.730B 46.31
QIAGEN (QGEN) Netherlands $12.309B 20.85
Biohaven Pharmaceutical Holding (BHVN) United States $9.150B 0.00
Emergent Biosolutions (EBS) United States $2.677B 6.46
Arcus Biosciences (RCUS) United States $2.522B 0.00
Myovant Sciences (MYOV) United Kingdom $1.905B 0.00
ADC Therapeutics SA (ADCT) Switzerland $1.799B 0.00
Zymeworks (ZYME) Canada $1.071B 0.00
Ambrx Biopharma (AMAM) United States $0.474B 0.00
SQZ Biotechnologies (SQZ) United States $0.341B 0.00
Enzo Biochem (ENZ) United States $0.160B 15.76